The FDA’s new support of a single study approach has drawn much discussion, raising questions as to whether conducting just one confirmatory study is a risky position for sponsors to take. In this blog, Andrew Garrett,...
-
ICON report first quarter 2025 results
Quarter one revenue was $2,001.3 million and quarter one adjusted EBITDA was $390.7 million or 19.5% of revenue.
-
Mural Health and ICON announce partnership
Mural Health Technologies, Inc., a patient-first clinical trial technology company, and ICON plc (NASDAQ: ICLR), a global healthcare intelligence and clinical research organisation, today announce a partnership to utilise the participant management and payments platform, Mural Link.
-
ICON reports fourth quarter and full year 2024 results
Full year net business wins of $9,974 million; a net book to bill of 1.20.
-
ICON portfolio of AI tools drives clinical trial efficiencies
ICON plc today announced the expansion of its portfolio of artificial intelligence (AI) tools that deliver efficiencies across the clinical trial process, including study startup, document management, resource forecasting and metrics reporting.
-
ICON issues financial guidance for full year 2025
ICON plc today announced its financial guidance for the year ending December 31, 2025.
-
Biomarker and trial optimisation needed to drive R&D progress in Alzheimer’s and related disorders – ICON survey
ICON plc today released the findings of a survey of over 120 biotech and pharma professionals developing treatments for neurodegenerative disorders.
-
ICON plc to present at the 43rd annual J.P. Morgan healthcare conference
ICON plc today announced that Dr. Steve Cutler, CEO of ICON plc, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Tuesday, January 14, 2025 at 3.45pm PST.
-
ICON and its employees celebrated for excellence in the field of clinical research
ICON plc has been honoured with numerous awards in the second half of 2024.
-
ICON announces appointment of Chief Operating Officer
Appointment of Barry Balfe as Chief Operating Officer (COO).
-
ICON survey highlights sustained investment in AI and digital R&D innovation, tempered by siloed adoption
Survey spotlights shifting expectations and more measured pace of innovation as use of digital solutions matures within the biotech and pharma industry.
